Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.45 |
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.43 |
| ▸ | NPY1R | P25929 | 3/20 | 0.41 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9668263 | 0.98 | NAAA (0.45) | HRH3NAAACXCR4NPY1RGNAO1 | |
| SCHEMBL9673755 | 0.95 | CXCR4 (0.48) | HRH3NAAACXCR4NPY1RCHRM5 | |
| SCHEMBL9676455 | 0.95 | CXCR4 (0.48) | HRH3NAAACXCR4NPY1RCHRM5 | |
| SCHEMBL9674013 | 0.93 | CXCR4 (0.49) | HRH3NAAACXCR4NPY1RGNAO1 | |
| SCHEMBL4157945 | 0.90 | GNAO1 (0.47) | HRH3NAAACXCR4GNAO1 | |
| SCHEMBL9673816 | 0.88 | CYP1A2 (0.42) | HRH3NAAACXCR4NPY1RCHRM5 | |
| SCHEMBL9676384 | 0.88 | CYP1A2 (0.42) | HRH3NAAACXCR4NPY1RCHRM5 | |
| SCHEMBL3816667 | 0.86 | SLC6A2 (0.42) | HRH3NAAACXCR4NPY1RCHRM5 | |
| SCHEMBL7403030 | 0.82 | GNAO1 (0.46) | HRH3NAAACXCR4NPY1RGNAO1 | |
| SCHEMBL7126423 | 0.81 | GNAO1 (0.57) | HRH3CXCR4NPY1RGNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7173135-B2 | Substituted 3-cyanoquinolines as MEK inhibitors | ASTRAZENECA AB (SE) | 2007-02-06 | — | — | US | disclosed |
| US-20060089382-A1 | 7-[3-(4-acetylpiperazin-1-yl)propoxy]-3-cyano-6-methoxy-4-[4-(3-methoxyprop-1-ynyl)-2,3-methylenedioxyanilino]quinoline; potent anti-tumour activity; inhibition of MEK enzymes involved in the MAPK kinase pathway, inhibiting the non-receptor tyrosine-specific protein kinases | ASTRAZENECA AB (SE) | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089382-A1 | 7-[3-(4-acetylpiperazin-1-yl)propoxy]-3-cyano-6-methoxy-4-[4-(3-methoxyprop-1-ynyl)-2,3-methylenedioxyanilino]quinoline; potent anti-tumour activity; inhibition of MEK enzymes involved in the MAPK kinase pathway, inhibiting the non-receptor tyrosine-specific protein kinases | MAPK1, MAPK3, MAPK4 | HRH3 1491/4885NAAA 1934/4885CXCR4 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.